16 results on '"Haluska, Frank G."'
Search Results
2. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
3. 4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients
4. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
5. Ponatinib in Heavily Pretreated Leukemia: 3-Year PACE Trial Results
6. Long-term Results of Ponatinib in CP-CML: 4-Year Minimum Follow-up of a Phase 1 Trial
7. EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
8. High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial
9. Safety and Durability of Ponatinib in Patients With Philadelphia Chromosome–Positive (Ph+) Leukemia: Long-term Follow-up of an Ongoing Phase 1 Study
10. Impact of Baseline Mutations on Response to Ponatinib and End of Treatment Mutation Analysis in Patients With Chronic Myeloid Leukemia
11. Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
12. Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
13. HLA-A2.1/Kb Transgenic Murine Dendritic Cells Transduced with an Adenovirus Encoding Human gp100 Process the Same A2.1-Restricted Peptide Epitopes as Human Antigen-Presenting Cells and Elicit A2.1-Restricted Peptide-Specific CTL
14. Mutational analysis of the CDK-4 gene in human pancreatic endocrine tumors
15. Identification and Mutation Analysis ofDOC-1R,a DOC-1 Growth Suppressor-Related Gene
16. Mechanisms of chromosome translocation in B- and T-cell neoplasia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.